MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
Maryland
Metropolitan Areas: Maryland
Montgomery County, Maryland
*Industry: Montgomery County
*Industry: Rockville, Maryland
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN)*
Organization & Developments: Supernus
Parents
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN)*
Children
*Engages in the development of medicines for the treatment of diseases of the central nervous system.
*It develops drug candidates for the treatment of epilepsy, Parkinson's disease, conduct disorders, depression, anxiety, and attention-deficit/hyperactivity disorders.
*Supernus has two FDA-approved drugs. These are Oxtellar XR and Trokendi XR. Both medications are once-daily anti-epileptics.
*Supernus Pharmaceuticals, Inc. is a former subsidiary of Shire Limited.
*The company, formerly known as Shire Laboratories, Inc., Supernus Pharmaceuticals
2020: A Super 'Pick-Up' By Supernus
2020: FDA hits Supernus with double whammy, handing biotech a CRL and RTF on same day_endpts
2020: Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD
2020: Supernus drug meets main goal of study in adults with ADHD
2020: Supernus: Launch Preparations In Progress
2020: Supernus' Makeover: A Work In Progress
2021: Supernus Pharmaceuticals: Solid Quarter, Solid Stock
2022: Supernus Pharmaceuticals: Shares Could Get Cheap_seekingalpha.com
2023: Supernus Pharmaceuticals: Derisked CNS Drug Portfolio Offers Attractive Buying Opportunity (NASDAQ:SUPN)
2023: Supernus: Sales Stretching Higher, But Not Reflected In Economic Leverage (NASDAQ:SUPN)
2024: FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease
2024: FDA issues second CRL to Supernus for Parkinson's drug-device combo
2024: Supernus links depression drug to fast responses in ph. 2 trial
2024: Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
2024: Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
2024: Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout_seekingalpha
2024: Supernus’ depression drug improved symptoms in two hours in Phase IIa study
2025: FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease
2025: Options shrink for Supernus depression drug candidate after key trial failure
2025: Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes
2025: Supernus: New Approval Holds Promise Of Increased Growth
Organization & Developments: Supernus (2015-2018)
Jumps
*Key People: Supernus
Finance & Acquisitions: Supernus